Chul S. Hyun, M.D., Ph.D. is CVH’s founding director. CVH staffs are consisted of public health personnel, nurses, and physicians who are experts in the field of viral Hepatitis. CVH has collaborative relationship with local hospitals, community organizations and physicians. CVH’s team of hepatitis experts, hospitals, community organizations, and volunteers work cooperatively in a multidisciplinary manner to ensure the highest quality of care for screening, education, vaccination, and linkage to care for viral hepatitis B and C infected individuals who will subsequently undergo monitoring and/or treatments.
CHUL S. HYUN obtained his B.A. from the Johns Hopkins University in 1977. After earning an M.D. from the University of Miami School of Medicine, he underwent internship and residency in Internal Medicine at Georgetown University Medical Center. Subsequently, he completed Gastroenterology and Liver Fellowship at Yale University School of Medicine. Dr. Hyun has also obtained a Ph.D. in Biophysics at the University of Rochester School of Medicine. His research training was further enriched in a postdoctoral fellowship in Physiology at the University of Chicago School of Medicine.
He is Board certified in Gastroenterology and has served as a faculty in the Division of Gastroenterology and Hepatology at the Weill Cornell Medical College. Dr. Hyun speaks frequently in both academic and community settings on various digestive disease topics, including viral hepatitis and stomach cancer. Dr. Hyun has served as a Board Member of the New Jersey State Board of Medical Examiners. He has also served as the president of Korean American Medical Association (KAMA, 2011-2013) and is the founding President of World Korean Medical Organization (WKMO, 2012-2015), a global network of 140,000 physicians of Korean descent devoted to promoting educational experience and networking among the physicians throughout the world. He is currently serving as the chair of the Asian American Stomach Cancer task Force (AASCTF), a non-profit organization devoted to raise awareness and to seek resources for Asian Americans on prevention, detection and treatment of stomach cancer.
There is a marked disparity between Asian Americans and White Americans in the prevalence of chronic hepatitis B and its complications. For instance, approximately 5-10 % of all Asian Americans have HBV infection compared with 0.1% of White Americans. In the United States, an estimated two million Americans are chronically infected with HBV, with up to 40,000 new infections each year. Nearly 1.4 million out of 2 million chronically infected people are unaware they have the virus. Other studies have also shown that less than 25% of Asian American HBV carriers have been diagnosed, suggesting a large population (undiagnosed) serve as reservoirs for transmission.
Hepatitis C virus (HCV) is a major cause of chronic liver diseases, including cirrhosis and liver cancer. Globally, 130-170 million people(2%–3% of the world’s population) are living with HCV infection, and each year, >350 000 die of cirrhosis and liver cancer. The epidemiology and burden of HCV infection varies throughout the world, with country-specific prevalence ranging from <1% to >10%.